Back to Best of AC17 Session - Novel Therapies in Lung Cancer - On-Demand
Best of AC17 Session - Novel Therapies in Lung Cancer - On-Demand

Best of AC17 Session - Novel Therapies in Lung Cancer - On-Demand

Lung cancer is the leading cause of cancer-related death in the United States. With the approval of novel targeted therapies and immunotherapy, the treatment landscape for lung cancer patients has changed dramatically. The use of these agents has dramatically improved survival and quality of life in patients with advanced or metastatic non–small cell lung cancer or extensive-stage small cell lung cancer. This session will review targeted and immunotherapy agents that are used in lung cancer treatment, current guideline recommendations, and outcome data comparing these novel agents to the standard-of-care regimens.

 

Content Area: Patient Management & Therapeutics

Product Details

Session from HOPA 2017 Annual Conference

Novel Therapies in Lung Cancer

 

Speaker: Eve Segal, PharmD BCOP

 

Learning Objectives:

1.      Describe the role of various signaling pathways involved in the development and progression of lung cancer.

2.      Review current treatment options for the treatment of squamous cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC).

3.      Discuss available data for the use of targeted therapies and immunotherapy in the management of advanced or metastatic NSCLC and extensive SCLC.

 

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member